Table 1.
Study characteristics.
| All | Male | Female | |
|---|---|---|---|
| N | 608 | 220 | 388 |
| Age at baseline visit | 80.55 ± 6.51 | 78.76 ± 6.72 | 81.57 ± 6.17 |
| Age at death, mean ± sd | 86.31 ± 4.73 | 84.94 ± 5.41 | 87.09 ± 4.11 |
| Female, n (%) | 388 (63.82%) | 0 (0.00%) | 388 (100.00%) |
| Post mortem interval (PMI), mean ± sd | 7.55 ± 6.01 | 7.80 ± 7.50 | 7.41 ± 4.98 |
| Proportion of neurons, mean ± sd | 0.45 ± 0.06 | 0.44 ± 0.06 | 0.45 ± 0.06 |
| Clinical diagnosis of cognitive status at baseline visit | |||
| No cognitive impairment, n (%) | 396 (65.13%) | 142 (64.55%) | 254 (65.46%) |
| Mild cognitive impairment (MCI), n (%) | 212 (34.87%) | 78 (35.45%) | 134 (34.54%) |
| Alzheimer’s disease dementia (AD)a, n (%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Other dementiaa, n (%) | 0 (0.00%) | 0 (0.00%) | 0 (0.00%) |
| Clinical diagnosis of cognitive status at last follow-up visit | |||
| No cognitive impairment, n (%) | 232 (38.16%) | 93 (42.27%) | 139 (35.82%) |
| Mild cognitive impairment (MCI), n (%) | 177 (29.11%) | 66 (30.00%) | 111 (28.61%) |
| Alzheimer’s disease dementia (AD), n (%) | 184 (30.26%) | 53 (24.09%) | 131 (33.76%) |
| Other dementiaa, n (%) | 8 (1.32%) | 5 (2.27%) | 3 (0.77%) |
| Clinical diagnosis of MDD at baseline visit | 30 (4.93%) | 9 (4.09%) | 21 (5.41%) |
aParticipants with a clinical diagnosis of dementia at baseline were excluded from the analysis sample.